Gardasil Immunogenicity With Needle-Free Injection
Phase of Trial: Phase III
Latest Information Update: 14 Jan 2019
Price : $35 *
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics
- Acronyms GINI
- 07 Jan 2019 Status changed from recruiting to completed.
- 08 Apr 2014 Planned end date changed from 1 Sep 2014 to 1 May 2016 as reported by ClinicalTrials.gov.
- 08 Apr 2014 Trial status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.